All In Biotech

Free tool

FAERS Monitor: Amondys 45

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213026 or its brand name (Amondys 45, Casimersen). Reports on generic versions are filed under their own applications.

Reports

986

Serious

166

17% of reports

Hospitalization

120

Death reported

11

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue282
  • no adverse event188
  • poor venous access125
  • device issue94
  • intentional dose omission81
  • malaise48
  • pyrexia46
  • covid-1933
  • illness31
  • influenza24
  • product distribution issue21
  • cough20
  • dehydration17
  • pneumonia17
  • fall16

Reports by year received

View as table
YearReports
202120
2022146
2023250
2024205
2025200
2026165

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,173 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
poor venous accessSignal125260.8221.231,722
intentional dose omissionSignal8160.849.34,695
product distribution issueSignal2148.431.7926
device issueSignal9422.418.51,905
no adverse eventSignal18822.219.53,806
product dose omission issueSignal28220.518.65,273
illnessSignal316.44.5137
influenzaSignal244.63.164
covid-19Signal334.02.972
pyrexiaSignal462.82.154
dehydrationSignal172.71.717
malaiseSignal482.31.836
cough201.51.03
pneumonia171.10.70
fall161.00.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.